Pseudomonas Prosthetic Joint Infections: A Review of 102 Episodes

Journal of Bone and Joint Infection
Neel B ShahElie F Berbari

Abstract

Background: The outcome of patients with Pseudomonas prosthetic joint infection (PS PJI) has not been well studied. The aim of this retrospective cohort study was to assess the outcome of patients with Pseudomonas PJI and to review risk factors associated with failure of therapy. Methods: Between 1/1969 and 12/2012, 102 episodes of PS PJI in 91 patients were identified. Results: The mean age at the time of diagnosis was 67.4 years; forty three percent had knee involvement. Over 40 percent had either diabetes mellitus or a history of gastrointestinal or genitourinary surgery. Nearly half (48 out of 102 episodes) received aminoglycoside monotherapy, while 25% received an anti-pseudomonal cephalosporin. The 2-year cumulative survival free from failure was 69% (95% CI, 56%-82%). Patients treated with resection arthroplasty, two-stage exchange, and debridement with implant retention had a 2-year cumulative survival free from failure of 80% (95% CI, 66%-95%), 83% (95% CI, 60%-100%), and 26% (95% CI, 23%-29%) respectively (P=0.0001). Conclusions: PS PJI's are associated with a high failure rate. Patients treated with debridement and implant retention had a worse outcome.

References

Jan 20, 2006·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·C E MarculescuD R Osmon
Oct 31, 2007·The Journal of Bone and Joint Surgery. American Volume·Steven M KurtzEdmund Lau
Apr 19, 2008·Clinical Orthopaedics and Related Research·Camelia E Marculescu, J Robert Cantey
Aug 9, 2008·Current Infectious Disease Reports·Andrej Trampuz, Werner Zimmerli
Aug 21, 2009·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Pang-Hsin HsiehSteve W Ueng
Jun 7, 2011·The Journal of Arthroplasty·Benjamin ZmistowskiJavad Parvizi
Oct 18, 2011·The Journal of Arthroplasty·William J Hozack, Javad Parvizi
Dec 12, 2012·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Douglas R OsmonUNKNOWN Infectious Diseases Society of America
Feb 2, 2013·Intensive Care Medicine·Mario TumbarelloMassimo Antonelli
Aug 1, 2014·The Journal of Infection·T AscioneS Esposito
Sep 28, 2014·Journal of Medical Microbiology·Raquel Cavalcanti DantasRosineide Marques Ribas
Dec 17, 2014·Clinica Chimica Acta; International Journal of Clinical Chemistry·Emanuela GallieraMassimiliano M Corsi Romanelli

❮ Previous
Next ❯

Citations

Apr 5, 2019·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Neel B ShahKenneth L Urish
Jun 17, 2020·Antimicrobial Agents and Chemotherapy·Devin SindeldeckerPaul Stoodley
Jul 18, 2020·JBJS Reviews·Ryan MillerNicolas S Piuzzi
Feb 27, 2021·Journal of Biomedical Materials Research. Part B, Applied Biomaterials·Augustina JeyanathanMelanie J Coathup
Apr 14, 2021·Clinical Orthopaedics and Related Research·Ken UeokaHiroyuki Tsuchiya
Sep 3, 2021·Biofilm·Devin Sindeldecker, Paul Stoodley
Oct 26, 2021·Antimicrobial Agents and Chemotherapy·Devin SindeldeckerPaul Stoodley

❮ Previous
Next ❯

Methods Mentioned

BETA
hysterectomy

Software Mentioned

JMP
REDCap

Related Concepts

Related Feeds

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.